3-异硫代氰酰基-1-甲基-1H-吡唑 | 114874-28-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 3-异硫代氰酰基-1-甲基-1H-吡唑
• 英文名称: 3-isothiocyanato-1-methyl-1H-pyrazole
• 英文别名: 3-isothiocyanato-1-methylpyrazole
• CAS: 114874-28-1
• 化学式: C₅H₅N₃S
• 分子量: 139.181
• InChiKey: FAHDFYMNSZOLPZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  62.3
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2933199090

反应信息

• 作为反应物：
  描述：

  3-异硫代氰酰基-1-甲基-1H-吡唑 、 氨基乙醛缩二乙醇 生成 N-2,2-diethoxyethyl-N'-(1-methylpyrazol-3-yl)thiourea
  参考文献：
  名称：

  YAMAMOTO, SUSUMU;SUMIDA, TAKUYA;SATO, TOSIAKI;MORIMOTO, KATSUYUKI;OYAKEH,+

  摘要：

  DOI：
• 作为产物：
  描述：

  1-Methyl-3-pyrazolyldithiocarbamic acid 生成 3-异硫代氰酰基-1-甲基-1H-吡唑
  参考文献：
  名称：

  YAMAMOTO, SUSUMU;SUMIDA, TAKUYA;SATO, TOSIAKI;MORIMOTO, KATSUYUKI;OYAKEH,+

  摘要：

  DOI：

文献信息

• [EN] THIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS CAUSED BY IGE<br/>[FR] DÉRIVÉS DE THIOPHÈNE POUR LE TRAITEMENT DE TROUBLES PROVOQUÉS PAR IGE
  申请人：UCB BIOPHARMA SRL

  公开号：WO2019243550A1

  公开（公告）日：2019-12-26

  Thiophene derivatives of formula (I) and a pharmaceutically acceptable salt thereof are provided. These compounds have utility for the treatment or prevention of disorders caused by IgE, such as allergy, type 1 hypersensitivity or familiar sinus inflammation.

  提供了公式（I）的噻吩衍生物及其药用可接受的盐。这些化合物对于治疗或预防由IgE引起的疾病具有用途，如过敏、1型超敏反应或家族性鼻窦炎。
• Development of a 2,4-Diaminothiazole Series for the Treatment of Human African Trypanosomiasis Highlights the Importance of Static–Cidal Screening of Analogues
  作者：Laura A. T. Cleghorn、Richard J. Wall、Sébastien Albrecht、Stuart A. MacGowan、Suzanne Norval、Manu De Rycker、Andrew Woodland、Daniel Spinks、Stephen Thompson、Stephen Patterson、Victoriano Corpas Lopez、Gourav Dey、Iain T. Collie、Irene Hallyburton、Robert Kime、Frederick R. C. Simeons、Laste Stojanovski、Julie A. Frearson、Paul G. Wyatt、Kevin D. Read、Ian H. Gilbert、Susan Wyllie

  DOI：10.1021/acs.jmedchem.3c00509

  日期：2023.7.13

  for human African trypanosomiasis (HAT) have improved significantly, there is still a need for new drugs with eradication now a realistic possibility. Here, we report the development of 2,4-diaminothiazoles that demonstrate significant potency against Trypanosoma brucei, the causative agent of HAT. Using phenotypic screening to guide structure–activity relationships, potent drug-like inhibitors were

  虽然非洲人类锥虫病 (HAT) 的治疗方案已显着改善，但仍然需要新药，并且目前根除锥虫病已成为现实。在此，我们报告了 2,4-二氨基噻唑的开发，该药物对HAT 的病原体布氏锥虫具有显着功效。使用表型筛选来指导结构-活性关系，开发了有效的药物样抑制剂。在 HAT 血淋巴阶段的动物模型中建立了概念验证。为了治疗感染的脑膜脑炎阶段，对化合物的药代动力学特性进行了优化，包括血脑屏障渗透性。然而，体内功效并未实现，部分原因是化合物从杀细胞作用机制演变为细胞抑制作用机制。随后的研究确定了参与肌醇生物合成途径的非必需激酶作为这些细胞抑制化合物的分子靶点。这些研究强调了治疗 HAT 的杀细胞药物的需求以及类似物静电杀灭筛选的重要性。
• Design, Synthesis, and Evaluation of New Thiadiazole-Based Direct Inhibitors of Enoyl Acyl Carrier Protein Reductase (InhA) for the Treatment of Tuberculosis
  作者：Roman Šink、Izidor Sosič、Matej Živec、Raquel Fernandez-Menendez、Samo Turk、Stane Pajk、Daniel Alvarez-Gomez、Eva Maria Lopez-Roman、Carolina Gonzales-Cortez、Joaquin Rullas-Triconado、Inigo Angulo-Barturen、David Barros、Lluís Ballell-Pages、Robert J. Young、Lourdes Encinas、Stanislav Gobec

  DOI：10.1021/jm501029r

  日期：2015.1.22

  Mycobacterial enoyl acyl carrier protein reductase (InhA) is a clinically validated target for the treatment of tuberculosis infections, a disease that still causes the death of at least a million people annually. A known class of potent, direct, and competitive InhA inhibitors based on a tetracyclic thiadiazole structure has been shown to have in vivo activity in murine models of tuberculosis infection. On the basis of this template, we have here explored the medicinal chemistry of truncated analogues that have only three aromatic rings. In particular, compounds 8b, 8d, 8f, 8l, and 8n show interesting features, including low nanomolar InhA IC50, submicromolar antimycobacterial potency, and improved physicochemical profiles in comparison with the tetracyclic analogues. From this series, 8d is identified as having the best balance of potency and properties, whereby the resolved 8d S-enatiomer shows encouraging in vivo efficacy.
• YAMAMOTO, SUSUMU;SUMIDA, TAKUYA;SATO, TOSIAKI;MORIMOTO, KATSUYUKI;OYAKEH,+
  作者：YAMAMOTO, SUSUMU、SUMIDA, TAKUYA、SATO, TOSIAKI、MORIMOTO, KATSUYUKI、OYAKEH,+

  DOI：——

  日期：——
• SUSUMU, YAMAMOTO;TAKUYA, KAKUTA;TOSHIAKI, SATO;KATSUSHI, MORIMOTO;EIICHI,+
  作者：SUSUMU, YAMAMOTO、TAKUYA, KAKUTA、TOSHIAKI, SATO、KATSUSHI, MORIMOTO、EIICHI,+

  DOI：——

  日期：——